Dáil Éireann Debate, Tuesday - 3 October 2017
360. Deputy Billy Kelleher asked the Minister for Health the status of the drug ocrelizumab for the treatment of multiple sclerosis; if the drug is being assessed by the National Centre for Pharmacoeconomics, NCPE; and if not, if it will be assessed in the near future. [41461/17]
Amharc ar fhreagraThe HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.
